PRIMARY OBJECTIVES:
I. To evaluate the safety and tolerability of low-dose oral minoxidil in patients with breast cancer and EIA.
II. To obtain preliminary data to support whether low-dose oral minoxidil is a reasonable alternative to topical minoxidil in patients with EIA.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients apply minoxidil foam topically to affected areas of the scalp once daily (QD) for up to 12 months in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive minoxidil orally (PO) QD for up to 12 months in the absence of disease progression or unacceptable toxicity.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women \>= 18 years of age
Established diagnosis of breast cancer stages I-IV
On endocrine therapy including tamoxifen or aromatase inhibitors with or without concurrent use of ovarian function suppression
Self-reporting hair loss since starting endocrine therapy
You may not be if
Pregnant or nursing women
Current chemotherapy use or prior chemotherapy use within the last 2 years
History of scarring/cicatricial alopecia or alopecia areata
Prior use of oral or topical minoxidil
Prior or ongoing use of spironolactone
Known sensitivity to minoxidil
Untreated hypothyroidism or iron deficiency as determined by thyroid stimulating hormone (TSH) with reflex free T4 and ferritin level \> 40 to be checked at the time of enrolling if not completed in the 12 months prior
Clareo Health | Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer
